Insider Buying: GSK plc (LON:GSK) Insider Purchases 8 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown purchased 8 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average price of GBX 1,399 ($18.00) per share, with a total value of £111.92 ($144.02).

GSK Price Performance

Shares of LON GSK traded down GBX 27.50 ($0.35) during mid-day trading on Tuesday, reaching GBX 1,369.50 ($17.62). 8,789,533 shares of the company traded hands, compared to its average volume of 10,130,556. GSK plc has a fifty-two week low of GBX 1,352.86 ($17.41) and a fifty-two week high of GBX 1,823.50 ($23.47). The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a market cap of £55.88 billion, a PE ratio of 1,207.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The stock has a fifty day simple moving average of GBX 1,512.80 and a 200-day simple moving average of GBX 1,583.74.

GSK Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. This represents a yield of 1.03%. The ex-dividend date is Thursday, November 14th. GSK’s payout ratio is 5,309.73%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several research reports. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,820 ($23.42) price target on shares of GSK in a research report on Tuesday, September 10th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($23.81) price objective on shares of GSK in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,842.50 ($23.71).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.